Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 27 of 47

26 Clinical OMICs January/February 2017 I n early 2007, the cost of sequencing a single human genome was around $10 million, according to data compiled by the National Human Genome Research Institute, and the decreasing cost was roughly following the path predicted by Moore's Law. This trend implies that the lowering cost of sequencing was directly related to increases in computing power. But all that changed by late 2007, as a variety of new, high-throughput sequenc- ing methods—referenced today under the catchall phrase "next-generation sequencing" (NGS)—began to replace the Sanger method. Less than four years later, the cost had plummeted to $10,000 amid wide-eyed chatter of the promise of the $1,000 genome. Now, we are nearly there. And not surprisingly, there is a new target—the $100 genome— which is a mere formality according to sequencing heavyweight Illumina, which launched NovaSeq in January, the tool it says will get us there. Today, NGS has democratized genomic research. It is routinely used by individ- ual pharmaceutical and academic researchers alike, with thousands of researchers worldwide routinely plumbing the depths of the coding regions of DNA in ways barely imaginable 10 years ago. The availability of broad, detailed datasets from this work has also infiltrated the clinic where doctors can now access genomic information to provide more precise care to their patients. But as the costs of sequencing have plummeted, the volume of generated Chris Anderson Editor in Chief Data Deluge Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems "People would say to me 'we have an overwhelming amount of work to do and it shuts down our cluster when we try to do it.'"—David Shaywitz, M.D., Ph.D., CMO, DNAnexus

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017